Skip to main content
رجوع
TXG logo

10x Genomics, Inc.

جودة البيانات: 100%
TXG
NASDAQ Healthcare Medical - Healthcare Information Services
KWD 20.91
▲ KWD 1.10 (5.55%)
القيمة السوقية: 2.67B
نطاق اليوم
KWD 19.82 KWD 21.12
نطاق 52 أسبوعًا
KWD 6.78 KWD 23.56
حجم التداول
2,734,253
متوسط 50 يوم / 200 يوم
KWD 20.09 / KWD 15.36
الإغلاق السابق
KWD 19.81

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -61.4 0.2
P/B 3.4 3.0
ROE % -5.8 3.6
Net Margin % -6.8 3.8
Rev Growth 5Y % 7.0 10.0
D/E 0.2 0.2

السعر المستهدف للمحللين

Hold
KWD 21.00 +0.4%
Low: KWD 17.00 High: KWD 25.00
ربحية السهم المستقبلية
-KWD 0.84
الإيرادات المقدّرة
612.25M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 -KWD 0.36
-KWD 0.37 – -KWD 0.35
841.03M 4
FY2029 -KWD 0.37
-KWD 0.38 – -KWD 0.36
777.69M 4
FY2028 -KWD 0.53
-KWD 0.85 – -KWD 0.07
706.50M 11

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-12 -KWD 0.20 -KWD 0.13 +35.9%
2025-11-06 -KWD 0.07 -KWD 0.22 -214.3%
2025-08-07 -KWD 0.35 KWD 0.28 +180.0%
2025-05-08 -KWD 0.45 -KWD 0.36 +20.0%
2025-02-12 -KWD 0.29 -KWD 0.40 -37.9%
2024-10-29 -KWD 0.34 -KWD 0.30 +11.8%
2024-08-08 -KWD 0.47 -KWD 0.32 +31.9%
2024-04-30 -KWD 0.46 -KWD 0.50 -8.7%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 7.00% annually over 5 years — modest growth
Debt/Equity of 0.20 — conservative balance sheet
Generating 130.12M in free cash flow
PEG of 0.61 suggests growth is underpriced
Capital efficient — spends only 0.92% of revenue on capex

النمو

Revenue Growth (5Y)
7.00%
Revenue (1Y)5.25%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-5.78%
ROIC-8.72%
Net Margin-6.77%
Op. Margin-17.25%

الأمان

Debt / Equity
0.20
Current Ratio4.46
Interest Coverage0.00

التقييم

P/E Ratio
-61.35
Forward P/EN/A
P/B Ratio3.35
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5.25% Revenue Growth (3Y) 1.93%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 7.00% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 642.82M Net Income (TTM) -43.54M
ROE -5.78% ROA -4.18%
Gross Margin 69.05% Operating Margin -17.25%
Net Margin -6.77% Free Cash Flow (TTM) 130.12M
ROIC -8.72% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.20 Current Ratio 4.46
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -61.35 Forward P/E N/A
P/B Ratio 3.35 P/S Ratio 4.16
PEG Ratio 0.61 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 4.36 Fwd Earnings Yield N/A
FCF Yield 4.87%
Market Cap 2.67B Enterprise Value 2.36B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 642.82M 610.79M 618.73M 516.41M 490.49M
Net Income -43.54M -182.63M -255.10M -166.00M -58.22M
EPS (Diluted) -0.35 -1.52 -2.18 -1.46 -0.53
Gross Profit 443.88M 414.48M 409.31M 396.02M 416.40M
Operating Income -110.89M -194.56M -265.33M -167.94M -52.91M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.04B 918.64M 965.14M 1.03B 1.02B
Total Liabilities 245.04M 208.50M 224.10M 223.24M 201.26M
Shareholders' Equity 796.33M 710.13M 741.04M 805.74M 817.57M
Total Debt 157.74M 82.61M 95.37M 95.18M 81.98M
Cash & Equivalents 473.97M 344.07M 359.28M 219.75M 587.45M
Current Assets 684.45M 584.39M 596.02M 635.04M 747.59M
Current Liabilities 153.45M 117.63M 127.16M 130.96M 110.36M